Jennifer Dearborn-Tomazos, MD
Neurology · New Haven, CTNPI 1144457755
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,000 of the $10,655 with a category attached, or 75.1%. E.r. Squibb & Sons, L.L.C. accounts for 85.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $9,133 and has fallen 98.4% since, to $149 in 2025.
Across 19 payments — averaging $560.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$9K
- Janssen Research & Development, LLC$1K
- Novo Nordisk$32
Across 14 payments — averaging $3709.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$26K
- Janssen Research & Development, LLC$22K
- Bristol Myers Squibb$5K
What the payments were for
- Consulting fees$8,00075%
- Travel & lodging$2,13920%
- Food & beverage$4835%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $9,133 |
| Janssen Research & Development, LLC | 10 | $1,490 |
| Novo Nordisk | 1 | $32 |
How this compares
$10,655 in reported general payments places this provider in the 75th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $17,126 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,813 |
| Levetiracetam | 57 | $1,356 |
| RizatriptanRizatriptan Benzoate | 16 | $1,011 |
| Lacosamide | 13 | $971 |
| Oxcarbazepine | 19 | $684 |
| Gabapentin | 48 | $345 |
| Propranolol Hcl ErPropranolol Hcl | 15 | $339 |
| Atorvastatin Calcium | 12 | $213 |
| Pregabalin | 15 | $118 |
| Nortriptyline Hcl | 14 | $53 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.